Marc Cobo - 10 Sep 2026 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Sep 2026, 16:24:02 UTC
Prior SEC filing
06 Jul 2026
Next SEC filing
05 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Aaron Chan, Attorney-in-Fact
Filing notes and source

Key filing fact

Marc Cobo filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (BBOT) on 14 Sep 2026.

Key facts

  • This page summarizes Marc Cobo's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (BBOT).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 14 Sep 2026, 16:24.

Change

  • Previous filing in this sequence was filed on 06 Jul 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001816654 Primary reporting owner

Cobo Marc

Relationship
Principal Accounting Officer
Address
BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Signature
/s/ Aaron Chan, Attorney-in-Fact
Signature date
14 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBOT transaction

Common Stock

Award

Transaction value
Shares
+9,038
Change %
+170%
Price
$0.000000*
Shares after
14,344
Date
10 Sep 2026
Ownership
Direct
Footnotes
F1
BBOT transaction

Common Stock

Tax liability

Transaction value
Shares
-203
Change %
-1.4%
Price
$5.52*
Shares after
14,141
Date
10 Sep 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBOT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+43,700
Change %
Price
$0.000000*
Shares after
43,700
Date
10 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
43,700
Exercise price
$5.52
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.

Footnote F2

Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of RSUs.

Footnote F3

1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .